Qilu Pharmaceutical Releases Latest Results of QL1604 plus Chemotherapy as First-Line Treatment for Patients with Advanced Cervical Cancer in the Phase II Study at ESMO Asia Congress 2022
- Sunday, December 4, 2022, 7:13
- PR Newswire
- Add a comment
JINAN, China, Dec. 4, 2022 /PRNewswire/ — Qilu Pharmaceutical, one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures, and distributes both finished formulations and Active Pharmaceutical Ingredients, announced that the results of the phase…
About the Author
admin has written 20736 stories on this site.